Teriparatide: A novel agent that builds new bone

Journal of the American Pharmacists Association

Volumn 43, Issue 4, 2003, Pages 535-537

  Freeman, Trish R ^a  

^a American Pharmacy Services Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE[1-34];

ARTICLE; BONE DENSITY; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HUMAN; MALE; OSTEOPOROSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

BONE DENSITY; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; OSTEOPOROSIS; TERIPARATIDE;

EID: 0642335869     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/154434503322226301     Document Type: Article

References (11)

1. Physician's Guide to Prevention and Treatment of Osteoporosis [publication online]. Washington, DC: National Osteoporosis Foundation. Available at: www.nof.org/physguide/index.htm. Accessed May 31, 2003.
2. McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am. 2003;32:253-71.
3. Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int. 2003;14:2-12.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321-33.
5. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3- year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282:637-45.
6. Silverman SL. Calcitonin. Endocrinol Metab Clin North Am. 2003;32:273-84.
7. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344: 1434-41.
8. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
9. Reeve J, Mitchell A, Tellez M, et al. Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur. J Bone Miner Metab. 2001;19:102-14.
10. Cosman F, Nieves J, Woelfert L, et al. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res. 1998;13:1051-5.
11. Forteo [prescribing information]. Indianapolis, Ind: Eli Lilly and Co; 2002. Available at: www.forteo.com. Accessed May 31, 2003.